Correlation of Chromosome Patterns in Human Leukemic Cells with Exposure to Chemicals and/or Radiation

FINAL REPORT
FOR THE PERIOD JANUARY 1, 1997 THROUGH DECEMBER 31, 1997

Janet D. Rowley, M.D.

The Franklin McLean Memorial Research Institute
The Department of Medicine
The University of Chicago
Chicago, Illinois

March, 1998

Prepared for
THE U.S. DEPARTMENT OF ENERGY
UNDER GRANT NO. DE-FG02-86ER60408

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED
DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.
DISCLAIMER

Portions of this document may be illegible electronic image products. Images are produced from the best available original document.
NOTICE

This report was prepared as an account of work sponsored by the United States Government. Neither the United States nor the United States Department of Energy, nor any of their employees, nor any of their contractors, subcontractors, or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product or process disclosed or represents that its use would not infringe privately-owned rights.

Janet D. Rowley, M.D., D.Sc.

A. Major Research Accomplishments

1. Introduction

This project began in 1962 when I became a member of the staff of the Argonne Cancer Research Hospital at the University of Chicago, which was fully funded by the Atomic Energy Commission. I was studying chromosome abnormalities with the use of autoradiography. In about 1965, I began to study the chromosome pattern in marrow cells from patients with leukemia and preleukemia. After a sabbatical 1970-71, I used chromosome banding techniques and discovered a number of recurring chromosome translocations in the cells of these patients. I showed that there was a non-random pattern of chromosome gains and losses in leukemia cells and that specific translocations were relatively consistently associated with particular morphologic subtypes of acute myeloid leukemia (AML) de novo. Moreover, I showed that these aberrations had some interesting variations in frequency that were related to the age of the patient. Thus recurring translocations tended to be more frequent in children whereas loss of chromosomes 5 and 7 tended to occur in older patients.

In 1977, my colleagues and I reported on the karyotype of leukemia cells in the first large (10 patients) series of Hodgkin's disease patients with a history of prior mutagenic therapy. I noted that 9 of these patients had loss of all or part of the long arm of chromosome 5 and that 5 patients also had loss of chromosome 7. This observation has been confirmed by many other investigators as well as by our continuing analysis of more patients.

I then embarked on an ongoing investigation as to the nature of the chromosome aberrations in t-AML/t-MDS because I felt that a careful analysis of these patients' cells would provide unique insights into the location of genes that were important in leukemogenesis and that this information might help us to determine which patients who appeared to have AML de novo, might, in fact, have mutagen related leukemia. This hope is still just that; however we are getting progressively closer to the gene or genes involved as we use ever more sophisticated molecular and cytogenetic techniques. Beginning in 1984, I embarked on a project to clone the genes at translocation breakpoints; in fact, we have cloned some of the genes involved in balanced translocations in t-AML and in AML de novo. My colleague, Dr. Michelle Le Beau has narrowed the location of some of the genes involved in deletions of the long arm of chromosomes 5 and 7 in t-AML as well as in AML de novo and she hopes to clone some of them in the next few years.
Since 1974, we have examined the karyotype of 260 patients with AML who have a
history of prior treatment with radiation and chemotherapy usually for a malignant disease.
We have sufficient clinical data on all patients so that we can correlate the type of prior
treatment with the chromosome abnormalities in the patient's leukemic cells (Tables 1, 2,
3). As can be seen in Table 1, 38 (14%) of these patients had received only radiation
therapy. In the past, we have concentrated on the deletions involving chromosomes 5
and/or 7 because these were the most common changes.

In the course of our analysis of these 260 t-AML patients, it became apparent that
there was another group of patients who lacked aberrations of chromosomes 5 and/or 7 and
whose leukemic cells had certain specific changes that were quite unusual for t-AML (Table
2). These patients have balanced translocations usually involving chromosome bands 11q23
(9 patients) that are associated with specific subsets of AML de novo and are common in
younger patients. Not only is there an increased frequency of aberrations of chromosome
11, there is also an increase in 21q22 translocations involving either chromosome
8[t(8;21)(q22;q22) or chromosome 3[t(3;21)(q26;q22)] (8 patients). We were the first to
describe the 3;21 translocation that with rare exceptions is only seen in t-AML or CML in
blast crisis. Finally other recurring translocations, such as the t(15;17)(q21;q12) (4 patients)
in acute promyelocytic leukemia (APL) or inv(16)(p13q22) (4 patients) in acute
myelomonocytic leukemia with abnormal eosinophils (M4Eo) are also occasionally seen in
the t-AML. Ironically, we used to comment emphatically that these aberrations were very
rarely seen in t-AML. This new form of t-AML also differs from the usual pattern, namely
losses of chromosome 5 and/or 7, in that it has a much shorter interval between treatment
and leukemia, rarely has a preleukemic phase, and appears to have a higher response rate
to treatment. Of special interest is the fact that these patients have usually received high
doses of topoisomerase II inhibitors, especially the epipodophyllotoxins, etoposide (VP16)
or teniposide (VM26). These latter drugs were first used with any frequency in the 1980s.
Just as we were the first to show that losses of chromosomes 5 and/or 7 were a common
feature of leukemia resulting from prior treatment with alkylating agents, we were also the
first to suggest that high doses of etoposide (VP16), one of the epidophyllotoxins, was
associated with translocations involving chromosome 11 band q23. Our group at the
University called attention to this association in 1987, when we reported on the greatly
increased risk of t-AML in a series of lung cancer patients treated with very high doses of
etoposide (Ratain, et al., Blood, 70:1412-1417, 1987). Our re-evaluation of the basis for
balanced translocations in t-AML began in 1986 after we analyzed our cytogenetic data on
cancer patients treated with epidophyllotoxins. Thus in our series of 119 patients with
non-small cell lung cancer who received aggressive chemotherapy with cisplatin and other
drugs, 24 (including 21 who received etoposide, VP16) survived more than one year. (14)
Nineteen of these patients died within another 14 months with no evidence of AML, one
patient is still alive, and the remaining four patients developed AML. It was noteworthy that
two of these four patients had a translocation involving 11q23 and M4 or M5 leukemia, the
third had a balanced translocation involving chromosomes X and 10, and the fourth patient
had a translocation involving chromosomes 5 and 7 leading to loss of both 5q and 7q with
definite t-AML characterized by typical trilineage dysplasia in bone marrow cells. Patients who developed leukemia had received significantly more etoposide than the nonleukemic patients (6,795 mg/m1 compared with 3,025 mg/m2, respectively). Another group of 35 patients received cyclophosphamide, doxorubicin, methotrexate and procarbazine; none of five patients who survived more than one year developed AML. We proposed that this unusual karyotypic pattern was related to the high dose of etoposide received by these patients. This association has now been confirmed by many other laboratory groups. More recently, we and others have found a very close correlation between the presence of balanced translocations involving 11q23 or 21q22 and exposure to topoisomerase II inhibitors.

We correlated the type of treatment with the presence of balanced and unbalanced translocations involving chromosome bands 11q23 and 21q22. We had nine patients with balanced translocations of 11q23 and eight patients with balanced translocations of 21q22 (Table 4). All patients in each group had received topo II inhibitors. This compares with 2 and 8 patients with unbalanced translocations involving these bands.

Dr. Pedersen-Bjergaard had previously reported on a similar analysis in his t-AML patients. The results are virtually identical. Of 91 patients, six had balanced 11q23 translocations and all of them had received topo II inhibitors. Similarly of five patients with 21q22 balanced translocations, all five had received topo II inhibitors. Of 80 other patients with unbalanced translocations involving these bands, only three had received topo II inhibitors, and all three had also received alkylating agents.

Beginning in 1989, my laboratory focused on the identification of the gene in 11q23 that was the target for these translocations in t-AML. We were successful in cloning the gene in 1991; we called it MLL for myeloid lymphoid leukemia. We have been heavily involved in studying its function. There are at least forty different translocations that involved MLL based in FISH and/or Southern blot analysis. Cloning these breakpoints, which has been completed for 16 translocations, has been very important. Most of the partner genes are new and thus we identify new targets for leukemogenesis. But some of the genes have been identified previously. In all of the translocations the challenge is to determine how the translocation alters the function of both MLL and the partner gene so that they lead to leukemia. We continued our functional analysis of the various domains of MLL, as well as of the partner genes to try to identify some of the changes in function of MLL as a consequence of the translocation. The involvement of MLL in acute leukemia following treatment with drugs which inhibit the function of topoisomerase II is being recognized in about 5-10% of MLL translocations.

More recently we have investigated the association of MLL rearrangements at 11q23 with the type of prior chemotherapy in t-AML patients. All patients had cytogenetically recognized 11q23 rearrangements. As can be seen in Table 5, every patient who had an
MLL rearrangement had received a topo II inhibitor, almost always an epipodophyllotoxin.

We have cloned the t(11;16)(q23;p13.3) and have shown that it involves MLL and CBP (CREB binding protein). We have studied eight t(11;16) patients with fluorescence in situ hybridization (FISH) using a probe for MLL and a cosmid contig covering the CBP gene. All patients had received treatment with topoisomerase II inhibitors for a prior malignant disease. Both probes were split in all eight patients and the two derivative (der) chromosomes were each labeled with both probes. Use of an approximately 100kb PAC cloned from the breakpoint of chromosome 16 from one patient revealed some variability in the breakpoint because it was on the der(16) in two patients, on the der(11) in two and split in four others. We assume that the critical fusion gene is 5'MLL/3'CBP. Our series of patients is unusual because two of them presented with a myelodysplastic syndrome (MDS) most similar to chronic myelomonocytic leukemia (CMMoL); MDS is rarely seen in 11q23 translocations either de novo or with t-AML. Using FISH and these same probes to analyze the lineage of bone marrow cells from one patient with CMMoL, we showed that the majority of mature monocytes contained the fusion genes as did some of the granulocytes and erythroblasts; none of the lymphocytes contained the fusion gene. The function of MLL is not well understood but many domains could target the MLL protein to particular chromatin configurations. CBP is an adapter protein that is involved in regulating transcription. It is also involved in histone acetylation which is thought to contribute to an increased level of gene expression. The fusion gene could alter the CBP protein such that it is constitutively active; alternatively it could modify the chromatin-association functions of MLL.

In conclusion, it has been clear for the last 15 years that cloning translocation breakpoints in both AML de novo and t-AML would provide the DNA probes required to determine whether the breakpoints in cytogenetically apparently similar translocations were identical at the level of DNA. Therefore we have pursued an analysis of rearrangements in both types of leukemia simultaneously. We have also cloned and sequenced several translocations in acute lymphoblastic leukemia and in chronic lymphatic leukemia. Recently we cloned the breakpoint in a number of translocations involving chromosome bands 11q23 and 21q22. We have cloned the gene which we called MLL, that is located in 11q23 that is involved in the 6;11, 9;11, and 11;19 translocations that are seen in AML de novo as well as in t-AML. (15-17) We have evidence that the breakpoint in 11q23 and in the t(9;11) is relatively similar in de novo and secondary AML. In addition, we have cloned the gene at the breakpoint in chromosome 21 in the t(3;21). These studies have provided DNA probes that will be very important for diagnosis and for monitoring the patient's response to treatment.


255. Thangavelu, M., Olopade, O.I., Beckman, E., Vardiman, J.W., Larson, R.A., McKeithan, T.W., Le Beau, M.M., Rowley, J.D. Clinical, morphologic and cytogenetic characteristics of patients with lymphoid malignancies characterized by both the t(14;18)(q32;q21) and the t(8;14)(q24;q32) or the t(8;22)(q24;q11). Genes Chrom Cancer, 2:147-148, 1990.


<table>
<thead>
<tr>
<th>Primary Diagnosis</th>
<th>N (%)</th>
<th>CT (%)</th>
<th>RT (%)</th>
<th>CMT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Malignant</td>
<td>14 (5)</td>
<td>11 (78)</td>
<td>1 (7)</td>
<td>2 (14)</td>
</tr>
<tr>
<td>Heme Malignancy</td>
<td>155 (57)</td>
<td>18 (25)</td>
<td>4 (6)</td>
<td>50 (69)</td>
</tr>
<tr>
<td>HD</td>
<td>72 (27)</td>
<td></td>
<td>4 (6)</td>
<td>50 (69)</td>
</tr>
<tr>
<td>NHL</td>
<td>61 (23)</td>
<td>29 (48)</td>
<td>1 (2)</td>
<td>31 (51)</td>
</tr>
<tr>
<td>Myeloma</td>
<td>21 (8)</td>
<td>17 (77)</td>
<td>0</td>
<td>5 (23)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (1%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solid Tumors</td>
<td>101 (37)</td>
<td>37 (37)</td>
<td>32 (32)</td>
<td>30 (30)</td>
</tr>
<tr>
<td>Breast</td>
<td>26 (10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovary</td>
<td>14 (5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>12 (4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>7 (3%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix</td>
<td>7 (3%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>35 (13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Totals</td>
<td>270 (100)</td>
<td>112 (42)</td>
<td>38 (14)</td>
<td>118 (44)</td>
</tr>
</tbody>
</table>
Table 2  
Cytogenetic Abnormalities in t-MDS/t-AML

<table>
<thead>
<tr>
<th>Number of Patients</th>
<th>270</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal number of patients</td>
<td>18 (6.6%)</td>
</tr>
<tr>
<td>Number with clonal abnormalities</td>
<td>252 (93.4%)</td>
</tr>
<tr>
<td>Number with abnormalities of chromosomes 5 and/or 7</td>
<td>191 (70.5%)</td>
</tr>
<tr>
<td>Chromosome 5 only</td>
<td>54 (19.9%)</td>
</tr>
<tr>
<td>Chromosome 7 only</td>
<td>76 (28.0%)</td>
</tr>
<tr>
<td>Chromosomes 5 and 7</td>
<td>61 (22.5%)</td>
</tr>
<tr>
<td>Other recurring abnormalities:</td>
<td>40* (14.8%)</td>
</tr>
<tr>
<td>t(11; q23)</td>
<td>9</td>
</tr>
<tr>
<td>t(3;21)/t(8;21)/t(21q22)</td>
<td>8*</td>
</tr>
<tr>
<td>t(15;17)</td>
<td>4</td>
</tr>
<tr>
<td>+8</td>
<td>7</td>
</tr>
<tr>
<td>inv(16)</td>
<td>4</td>
</tr>
<tr>
<td>-13/del(13q)</td>
<td>3</td>
</tr>
<tr>
<td>del(20q)</td>
<td>1</td>
</tr>
<tr>
<td>del(11q)</td>
<td>1</td>
</tr>
<tr>
<td>+11</td>
<td>1</td>
</tr>
<tr>
<td>+21</td>
<td>1</td>
</tr>
<tr>
<td>-Y</td>
<td>1</td>
</tr>
<tr>
<td>Other abnormalities</td>
<td>22 (8.1%)</td>
</tr>
</tbody>
</table>

*One patient had both a del(5q) and t(3;21); thus, these columns total 253, rather than 252 with abnormal karyotypes.
## Table 3

Primary Diagnosis, Primary Therapy and Clonal Cytogenetic Abnormalities in 270 Patients with Therapy-Related Myeloid Leukemia

<table>
<thead>
<tr>
<th>Number of Patients (Row percentages)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Diagnosis</strong></td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td>Non-malignant</td>
</tr>
<tr>
<td><strong>Heme Malignancy</strong></td>
</tr>
<tr>
<td>HD</td>
</tr>
<tr>
<td>NHL</td>
</tr>
<tr>
<td>Myeloma</td>
</tr>
<tr>
<td><strong>Solid Tumor</strong></td>
</tr>
<tr>
<td>Breast</td>
</tr>
<tr>
<td>Ovary</td>
</tr>
<tr>
<td>Prostate</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
</tr>
</tbody>
</table>

| **Primary Therapy**    |       |        |          |           |        |           |
| CT Only                | 22* (20) | 33 (29) | 23 (21) | 26* (23) | 9 (8) | 112 (42%) |
| RT Only                | 11 (29) | 6 | 6 | 11 (29) | 4 | 38 (14%) |
| CMT                    | 20 (17) | 37 (31) | 32 (27) | 24 (20) | 5 (4) | 118 (44%) |

*BG had both del(5q) and t(3;21)
### Table 4

**Relationship Between Prior Chemotherapy and Clonal* Chromosomal Translocations in 260 Patients with t-MDS/t-AML**

<table>
<thead>
<tr>
<th></th>
<th>ATTop Only</th>
<th>ATTop + AA</th>
<th>AA Only</th>
<th>Other Treatment</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number Studied</td>
<td>25</td>
<td>110</td>
<td>106</td>
<td>19</td>
<td>260</td>
</tr>
<tr>
<td>Balanced translocation band 11q23</td>
<td>3</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Balanced translocation band 21q22</td>
<td>2</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Unbalanced translocation band 11q23</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Unbalanced translocation band 21q22</td>
<td>3</td>
<td>1</td>
<td>6</td>
<td>1</td>
<td>11</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- ATTop, chemotherapy agents that target DNA topoisomerase II; AA, alkylating agents. Balanced translocations involving band 11q23 or 21q22 were significantly associated with prior ATTop exposure (p=0.003, Fisher's exact test, two sided).
Table 5 Association of MLL Rearrangements and Prior Therapy with Topoisomerase II Reactive Drugs

<table>
<thead>
<tr>
<th>Prior treatment with topo II inhibitor</th>
<th>+</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>MLL rearrangement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>9*</td>
<td>0</td>
</tr>
<tr>
<td>-</td>
<td>1#</td>
<td>2†</td>
</tr>
</tbody>
</table>

The numbers of patients in each category is listed. The association of MLL rearrangements with prior topo II exposure was statistically significant (p=0.01, Fisher’s exact test).23

* - All patients had balanced translocations
# - Patient had an unbalanced translocation
† - Both patients had del(11)(q23)